Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary

Walter M. Klein, Robert J Kurman

Research output: Contribution to journalArticle

Abstract

c-kit is a proto-oncogene that codes for a transmembrane tyrosine kinase receptor (CD117). The gene product KIT is constitutively overexpressed in mastocytosis and gastrointestinal stromal tumors. Recently the use of the tyrosine kinase inhibitors, such as STI-571, has resulted in the successful treatment of bcr-abl-positive leukemias and gastrointestinal stromal tumors. In gastrointestinal stromal tumors, immunostaining for c-kit is diffusely positive. Because the expression of c-kit in mesenchymal tumors of the uterus and ovary has not been previously studied, we evaluated its expression in 38 of these tumors by immunohistochemistry. The number of positive labeled/total tumors were as follows: 0/8 malignant mullerian mixed tumors, 4/7 ovarian fibrosarcomas, 0/1 clear-cell ovarian sarcoma, 0/4 uterine leiomyosarcomas, 1/10 low-grade endometrial stromal sarcomas, 0/2 high-grade endometrial stromal sarcomas, and 3/6 endometrial stromal nodules. In all positive cases, no more than 5% of the cells were labeled. In conclusion, unlike gastrointestinal stromal tumors, mesenchymal tumors of the uterus and ovary rarely express c-kit. Therefore, it is unlikely that patients with these tumors will benefit from treatment with the currently available tyrosine kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)181-184
Number of pages4
JournalInternational Journal of Gynecological Pathology
Volume22
Issue number2
DOIs
StatePublished - Apr 2003

Fingerprint

Proto-Oncogene Proteins c-kit
Gastrointestinal Stromal Tumors
Uterus
Ovary
Neoplasms
Protein-Tyrosine Kinases
Mullerian Mixed Tumor
Endometrial Stromal Tumors
Endometrial Stromal Sarcoma
Clear Cell Sarcoma
Malignant Mixed Tumor
Mastocytosis
Proto-Oncogenes
Leiomyosarcoma
Fibrosarcoma
Receptor Protein-Tyrosine Kinases
Leukemia
Immunohistochemistry
Therapeutics
Genes

Keywords

  • c-kit
  • Mesenchymal tumors
  • Ovary
  • Uterus

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. / Klein, Walter M.; Kurman, Robert J.

In: International Journal of Gynecological Pathology, Vol. 22, No. 2, 04.2003, p. 181-184.

Research output: Contribution to journalArticle

@article{595c6e0d83ce48efb8a52ae4a3111326,
title = "Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary",
abstract = "c-kit is a proto-oncogene that codes for a transmembrane tyrosine kinase receptor (CD117). The gene product KIT is constitutively overexpressed in mastocytosis and gastrointestinal stromal tumors. Recently the use of the tyrosine kinase inhibitors, such as STI-571, has resulted in the successful treatment of bcr-abl-positive leukemias and gastrointestinal stromal tumors. In gastrointestinal stromal tumors, immunostaining for c-kit is diffusely positive. Because the expression of c-kit in mesenchymal tumors of the uterus and ovary has not been previously studied, we evaluated its expression in 38 of these tumors by immunohistochemistry. The number of positive labeled/total tumors were as follows: 0/8 malignant mullerian mixed tumors, 4/7 ovarian fibrosarcomas, 0/1 clear-cell ovarian sarcoma, 0/4 uterine leiomyosarcomas, 1/10 low-grade endometrial stromal sarcomas, 0/2 high-grade endometrial stromal sarcomas, and 3/6 endometrial stromal nodules. In all positive cases, no more than 5{\%} of the cells were labeled. In conclusion, unlike gastrointestinal stromal tumors, mesenchymal tumors of the uterus and ovary rarely express c-kit. Therefore, it is unlikely that patients with these tumors will benefit from treatment with the currently available tyrosine kinase inhibitors.",
keywords = "c-kit, Mesenchymal tumors, Ovary, Uterus",
author = "Klein, {Walter M.} and Kurman, {Robert J}",
year = "2003",
month = "4",
doi = "10.1097/00004347-200304000-00011",
language = "English (US)",
volume = "22",
pages = "181--184",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary

AU - Klein, Walter M.

AU - Kurman, Robert J

PY - 2003/4

Y1 - 2003/4

N2 - c-kit is a proto-oncogene that codes for a transmembrane tyrosine kinase receptor (CD117). The gene product KIT is constitutively overexpressed in mastocytosis and gastrointestinal stromal tumors. Recently the use of the tyrosine kinase inhibitors, such as STI-571, has resulted in the successful treatment of bcr-abl-positive leukemias and gastrointestinal stromal tumors. In gastrointestinal stromal tumors, immunostaining for c-kit is diffusely positive. Because the expression of c-kit in mesenchymal tumors of the uterus and ovary has not been previously studied, we evaluated its expression in 38 of these tumors by immunohistochemistry. The number of positive labeled/total tumors were as follows: 0/8 malignant mullerian mixed tumors, 4/7 ovarian fibrosarcomas, 0/1 clear-cell ovarian sarcoma, 0/4 uterine leiomyosarcomas, 1/10 low-grade endometrial stromal sarcomas, 0/2 high-grade endometrial stromal sarcomas, and 3/6 endometrial stromal nodules. In all positive cases, no more than 5% of the cells were labeled. In conclusion, unlike gastrointestinal stromal tumors, mesenchymal tumors of the uterus and ovary rarely express c-kit. Therefore, it is unlikely that patients with these tumors will benefit from treatment with the currently available tyrosine kinase inhibitors.

AB - c-kit is a proto-oncogene that codes for a transmembrane tyrosine kinase receptor (CD117). The gene product KIT is constitutively overexpressed in mastocytosis and gastrointestinal stromal tumors. Recently the use of the tyrosine kinase inhibitors, such as STI-571, has resulted in the successful treatment of bcr-abl-positive leukemias and gastrointestinal stromal tumors. In gastrointestinal stromal tumors, immunostaining for c-kit is diffusely positive. Because the expression of c-kit in mesenchymal tumors of the uterus and ovary has not been previously studied, we evaluated its expression in 38 of these tumors by immunohistochemistry. The number of positive labeled/total tumors were as follows: 0/8 malignant mullerian mixed tumors, 4/7 ovarian fibrosarcomas, 0/1 clear-cell ovarian sarcoma, 0/4 uterine leiomyosarcomas, 1/10 low-grade endometrial stromal sarcomas, 0/2 high-grade endometrial stromal sarcomas, and 3/6 endometrial stromal nodules. In all positive cases, no more than 5% of the cells were labeled. In conclusion, unlike gastrointestinal stromal tumors, mesenchymal tumors of the uterus and ovary rarely express c-kit. Therefore, it is unlikely that patients with these tumors will benefit from treatment with the currently available tyrosine kinase inhibitors.

KW - c-kit

KW - Mesenchymal tumors

KW - Ovary

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=0037378396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037378396&partnerID=8YFLogxK

U2 - 10.1097/00004347-200304000-00011

DO - 10.1097/00004347-200304000-00011

M3 - Article

C2 - 12649674

AN - SCOPUS:0037378396

VL - 22

SP - 181

EP - 184

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 2

ER -